« Return to News | Clinical Intelligence

FDA issues complete response to Protalix

Tuesday, March 1, 2011 08:33 AM

The FDA has issued a complete response letter for Protalix's Gaucher's disease drug taliglucerase alfa. Protalix won't be required to conduct any additional clinical studies, but that didn't stop its stock from plunging on the news, FierceBiotech reported.

The FDA's main concerns were with clinical and chemistry, manufacturing and controls. The agency wants additional data from Protalix's switchover trial and long-term extension trial. At the time the NDA was submitted, full information from these trials was not available, the company noted in a release. The FDA wants information on testing specifications and assay validation.

"While we are disappointed by the receipt of the Complete Response Letter, we appreciate the FDA's efforts to complete the review of our NDA,” said Protalix CEO David Aviezer. “We noted that the FDA did not request additional clinical studies. Moreover, the FDA inspected our manufacturing facilities, finding them acceptable. FDA also did not identify any issues in its audit of our clinical sites." The company said it will meet with the FDA to determine its next steps.

Gaucher's is a rare genetic disease in which lipids accumulate in the organs, resulting in organ enlargement and bone pain. Pfizer has partnered with Protalix since 2009 on the drug, an oral recombinant protein therapeutic. If approved, taliglucerase alfa could erode market share of Genzyme's Cerezyme, which has faced shortages due to manufacturing problems.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.